modelTechnetium99mtcExametazi
Extends from Pharmacolibrary.Drugs.ATC.V.V09HA02.
Information
| name: | Technetium99mtcExametazimeLabelledCells | |
| ATC code: | V09HA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 370 | mg |
| volume of distribution: | 5 | L |
| clearance: | 0.1 | L/h |
| other parameters in model implementation | ||
Technetium (99mTc) exametazime labelled cells are autologous white blood cells (typically leukocytes) that are labelled ex vivo with the radiotracer 99mTc-exametazime. The resulting radiolabelled cells are used for radionuclide imaging, particularly to detect sites of infection or inflammation in nuclear medicine diagnostics. The product is approved for clinical use in many countries as a radiopharmaceutical.
Pharmacokinetics
No published pharmacokinetic model parameters for technetium (99mTc) exametazime labelled cells in humans were found. However, after intravenous administration of labelled cells, activity is seen initially in the lungs, then redistribution occurs with uptake in the liver, spleen, and bone marrow. Parameters below are rough estimates based on analogous labelled cell imaging agents and clinical practice.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)